News - NFE2L2 expression

3ms

Effects of antioxidant-rich Lactiplantibacillus plantarum inoculated alfalfa silage on rumen fermentation, antioxidant and immunity status, and mammary gland gene expression in dairy goats. (PubMed, J Anim Sci Biotechnol)

These findings indicated that feeding L. plantarum 24-7 inoculated alfalfa silage not only improved rumen fermentation and milk quality in lactating dairy goats but also boosted their immunity and antioxidant status by modulating the expression of several genes related to antioxidant and inflammation in the mammary gland.

3 months ago

Journal

IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • HMOX1 (Heme Oxygenase 1) • IL10 (Interleukin 10) • GPX2 (Glutathione peroxidase 2 (gastrointestinal)) • IL1B (Interleukin 1, beta) • NOX4 (NADPH Oxidase 4) • CAT (Catalase) • SOD2 (Superoxide Dismutase 2) • SOD3 (Superoxide dismutase 3)

HMOX1 expression • NFE2L2 expression

6ms

High Expression of NRF2 and Low Expression of KEAP1 Predict Worse Survival in Patients With Operable Triple-Negative Breast Cancer. (PubMed, J Breast Cancer)

High NRF2 and low KEAP1 expressions independently predicted poor survival in patients with operable TNBC. Further investigations are warranted to examine the possible therapeutic benefits of targeting the KEAP1-NRF2 pathway for TNBC treatment.

6 months ago

Journal

KEAP1 (Kelch Like ECH Associated Protein 1)

KEAP1 expression • NFE2L2 expression

10ms

Roles of NRF2 in DNA damage repair. (PubMed, Cell Oncol (Dordr))

NRF2 participates in a variety of DNA repair pathways and plays important roles in maintaining genome stability. NRF2 is a potential target for cancer treatment.

10 months ago

Review • Journal

NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)

NFE2L2 mutation • NFE2L2 expression

12ms

NRF2 INHIBITION IN COMBINATION WITH IBRUTINIB IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA– AN IN VITRO STUDY (EHA 2023)

Our results suggest that BRU could be a potential pharmacological agent for the therapeutic approach of CLL, in monotherapy and as an adjuvant to treatment with IBR. Chronic lymphocytic leukemia, Apoptosis, ibrutinib, Transcription factor

12 months ago

Preclinical • Combination therapy

NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • HMOX1 (Heme Oxygenase 1) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • ANXA5 (Annexin A5)

HMOX1 expression • KEAP1 expression • NFE2L2 expression

Imbruvica (ibrutinib)

12ms

MOLECULAR MECHANISMS OF RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA: AN IN VITRO STUDY (EHA 2023)

Different IMiDs are currently used in clinical practice in combination with PI, such as Lenalidomide (LEN) and Pomalidomide (POM), having both cereblon as the main target...Aims: This project's focus was to evaluate the molecular mechanism of resistance to IMiDs resistance, namely LEN and POM, in MM cells and assess the cross-resistance to Bortezomib (BTZ)... The resistant models developed show different degrees of resistance according to IMiD and cell line. In LEN- resistant models, H929-RL and U-266RL cells presented an IC 25 6.5x and over 1000x higher compared to parental cells, respectively. The U-266RP cells showed an IC 25 500x higher than U-266 cells.

12 months ago

Preclinical • IO biomarker • Immunomodulating

MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • CRBN (Cereblon) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • ABCG2 (ATP Binding Cassette Subfamily G Member 2) • NQO1 (NAD(P)H dehydrogenase, quinone 1) • REL (REL Proto-Oncogene) • RELA (RELA Proto-Oncogene) • SLC2A1 (Solute Carrier Family 2 Member 1)

BCL2 expression • MYC expression • CRBN expression • NFE2L2 expression

lenalidomide • bortezomib • pomalidomide • thalidomide